Anita Mahajan, MD, professor, The University of Texas MD Anderson Cancer Center, discusses a recent study into the role of stereotactic radiosurgery in treating brain metastases.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More